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Background {#ams2364-sec-0004}
==========

Although the frequency of extracorporeal membrane oxygenation (ECMO) use in respiratory failure is increasing, only half of such cases are discharged or transferred, and high survival rates have not yet been achieved.[1](#ams2364-bib-0001){ref-type="ref"} The indications for ECMO remain controversial, especially in patients who are immunosuppressed or have non‐recoverable comorbidities. There are several reports of successful ECMO use for severe hypoxia in patients with HIV/AIDS.[2](#ams2364-bib-0002){ref-type="ref"}, [3](#ams2364-bib-0003){ref-type="ref"}, [4](#ams2364-bib-0004){ref-type="ref"}, [5](#ams2364-bib-0005){ref-type="ref"}, [6](#ams2364-bib-0006){ref-type="ref"}, [7](#ams2364-bib-0007){ref-type="ref"}, [8](#ams2364-bib-0008){ref-type="ref"}, [9](#ams2364-bib-0009){ref-type="ref"}, [10](#ams2364-bib-0010){ref-type="ref"} However, key therapeutic issues, such as mechanical ventilation (MV) settings, indications for ECMO, and the timing of antiretroviral therapy (ART), have not always been discussed in these reports. A case of acute respiratory distress syndrome in a patient with novel HIV/AIDS, who was successfully treated with veno‐venous (V‐V) ECMO and discharged, is presented.

Case {#ams2364-sec-0005}
====

A 47‐year‐old man with an unknown medical history was admitted to our tertiary medical center due to worsening shortness of breath. He had been in his usual state of health until he developed oral white plaques 3 months prior to admission. In the previous month, he had mild chest pain, productive cough, and a mild fever. On the day of admission, he was found lying down with severe shortness of breath. He presented with a respiratory rate of 42 breaths/min and unmeasurable O~2~ saturation, and was brought in by ambulance for severe respiratory failure. Physical examination showed coarse crackles over the right lung. Chest computed tomography (Fig. [1](#ams2364-fig-0001){ref-type="fig"}A) showed diffuse, bilateral, ground glass opacities. He was in severe respiratory failure with a PaO~2~/F~I~O~2~ ratio of 110.8 requiring intubation and MV.

![Chest computed tomography and X‐ray findings in a patient with HIV/AIDS and severe acute respiratory distress syndrome treated with veno‐venous extracorporeal membrane oxygenation. A, Initial chest computed tomography. B, Portable chest X‐ray on hospital day 4. C, Portable chest X‐ray on hospital day 11, showing prominent bilateral consolidation. D, Portable chest X‐ray on hospital day 17, showing decreased lung consolidation.](AMS2-5-384-g001){#ams2364-fig-0001}

The diagnosis of HIV infection was suspected on admission because of positive screening for HIV antigen--antibody (CLIA test), and it was later confirmed by a CD4^+^ T‐cell count of 6/μL and an HIV viral load of 1.4 × 10^5^ copies/mL. Simultaneously, *Pneumocystis jirovecii* pneumonia was highly suspected on admission based on clinical signs, diagnostic imaging, a lactate dehydrogenase level of 1,511 U/L, and an elevated β‐D‐glucan level of 25.9 pg/mL. His respiratory failure was so severe that we believed it was safer and more appropriate to start treatment for *P. jirovecii* pneumonia than to carry out bronchoalveolar lavage. Polymerase chain reaction test was not available. Although a definitive diagnosis of *P. jirovecii* pneumonia was not made, treatment with trimethoprim/sulfamethoxazole and prednisolone was started appropriately, and piperacillin/tazobactam and vancomycin were started to cover concomitant bacterial infections from admission. Sputum culture was negative for common pneumonia pathogens, urine *Streptococcus pneumoniae* antibody was negative, and blood cultures were negative; therefore, concomitant bacterial infection was considered unlikely, and piperacillin/tazobactam and vancomycin were discontinued after 4 days.

Four days after his admission, the patient developed progressive hypoxia requiring F~I~O~2~ 0.5/positive end‐expiratory pressure (PEEP) 10 increasing to F~I~O~2~ 0.7/PEEP 15 within 1 day and worsening consolidation on X‐ray (Fig. [1](#ams2364-fig-0001){ref-type="fig"}B). The Murray score was 3 points, and progressive respiratory failure was predicted. As he developed progressive symptoms despite appropriate care and had no prospect of improvement within 7 days, beyond which time ECMO use is associated with worse outcomes, and because there have been some case reports of successful ECMO use in cases of acute respiratory distress syndrome with novel HIV/AIDS, it was decided to initiate V‐V ECMO (Capiox; Terumo, Tokyo, Japan).

Conventional MV settings (F~I~O~2~ \< 0.4 and plateau pressure \< 25) were used (Table [1](#ams2364-tbl-0001){ref-type="table"}), maintaining SaO~2~ \> 80%, hemoglobin \> 12 g/dL, and platelets \> 10 × 10^4^/μL with transfusion based on protocols or Extracorporeal Life Support Organization (ELSO) guidelines.[11](#ams2364-bib-0011){ref-type="ref"}, [12](#ams2364-bib-0012){ref-type="ref"} The patient required two membrane exchanges, and after the second membrane replacement, surgical tracheostomy was carried out following heparin antagonization with protamine; by that time his oxygen demand decreased to F~I~O~2~ 0.3/PEEP 10, and significant X‐ray improvement was noted (Fig. [1](#ams2364-fig-0001){ref-type="fig"}C,D). His course was further complicated by mediastinal emphysema before ECMO decannulation, which was managed supportively. He was successfully decannulated after 19 days of ECMO, because arterial blood gases were satisfactory for at least 8 hours with a blood flow of 1.5 L/min and a sweep gas of 0.5 L/min (parameters from a previous article).[6](#ams2364-bib-0006){ref-type="ref"}

###### 

Mechanical ventilation (MV) settings in a patient with HIV/AIDS and severe acute respiratory distress syndrome treated with veno‐venous extracorporeal membrane oxygenation (ECMO)

  Hospital day                                       Mode   F~[I]{.ul}~O~2~   Vt (mL) or PIP (cmH~2~O)   PEEP (cmH~2~O)   RR (/min)
  -------------------------------------------------- ------ ----------------- -------------------------- ---------------- -----------
  Day 1                                              VCV    0.50              420 mL                     8                12
  Day 2                                              PCV    0.45              15                         8                12
  Day 3                                              PCV    0.40              15                         10               8
  Day 4                                              PCV    0.50              15                         10               8
  Day 5                                              PCV    0.70              18                         15               8
  **ECMO introduced**                                                                                                     
  Day 6                                              PSV    0.40                                         8                
  Day 9                                              PCV    0.50              18                         6                15
  Day 11                                             PCV    0.40              20                         10               8
  **Fixed MV settings and changed only as needed**                                                                        
  Day 23                                             PCV    0.40              25                         8                20
  PCV                                                0.60   25                8                          20               
  **Increased F~I~O~2~, then ECMO decannulated**                                                                          

PCV, pressure control ventilation; PEEP, positive end‐expiratory pressure; PIP, peak inspiratory pressure; PSV, pressure support ventilation; RR, respiratory rate; VCV, volume control ventilation; Vt, tidal volume.
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Several microbial infections concurred during his hospital stay (Table [2](#ams2364-tbl-0002){ref-type="table"}). Detection of cytomegalovirus antigen in neutrophils came back positive and ganciclovir was started on hospital day 7. The patient\'s respiratory status worsened on ECMO and because atypical pneumonia pathogens had not been covered since admission, levofloxacin was added on hospital day 10 and a 14‐day course was completed. In addition, *P. jirovecii* pneumonia treatment was switched to pentamidine per recommendation from consultants followed by initiation of prophylactic treatment with azithromycin for mycobacterium avium complex on hospital day 21.

###### 

Antibiotic, antimycotic, and antiviral treatment during extracorporeal membrane oxygenation (ECMO) use in a patient with HIV/AIDS and severe acute respiratory distress syndrome

                                       Admission                                Day 5                                    Day 7         Day 10         Day 18         Day 20         Day 21         Day 23
  ------------------------------------ ---------------------------------------- ---------------------------------------- ------------- -------------- -------------- -------------- -------------- --------------
  **Bacterial pneumonia**                                                                                                                                                                          
                                       Piperacillin/tazobactam and vancomycin   Piperacillin/tazobactam and vancomycin                 Levofloxacin   Levofloxacin   Levofloxacin   Levofloxacin   Levofloxacin
  **Novel HIV/AIDS**                                                                                                                                                                               
  *Pneumocystis jirovecii* pneumonia   SMX + TMP                                SMX + TMP                                SMX + TMP     SMX + TMP      Pentamidine    Pentamidine    Pentamidine    Pentamidine
  CMV                                                                                                                    Ganciclovir   Ganciclovir    Ganciclovir    Ganciclovir                   
  MAC                                                                                                                                                                               Azithromycin   Azithromycin
  **ECMO**                                                                                                                                                                                         
                                                                                Initiated                                                                                                          Decannulated

CMV, cytomegalovirus; MAC, mycobacterium avium complex; SMX, sulfamethoxazole; TMP, trimethoprim.
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Thirteen days after decannulation, after the successful treatment regimen and to avoid reported immune reconstitution inflammatory syndrome (IRIS), ART was started. Subsequently, the patient was weaned off ventilator support. The patient was then moved to a regular ward and eventually discharged home ambulatory.

Discussion {#ams2364-sec-0006}
==========

The course of this patient highlighted some important clinical issues. The discharge rate of acute respiratory distress syndrome cases with HIV/AIDS treated with ECMO is reportedly better than that of general patients treated with V‐V ECMO (67% versus 58%, Table [3](#ams2364-tbl-0003){ref-type="table"}).[1](#ams2364-bib-0001){ref-type="ref"} Although there is no absolute contraindication to V‐V ECMO in the guidelines, treating immune‐compromised patients, including those with HIV/AIDS, with V‐V ECMO is sometimes considered controversial.[11](#ams2364-bib-0011){ref-type="ref"}, [12](#ams2364-bib-0012){ref-type="ref"} However, previous reports and the present case show that severe respiratory failure with HIV/AIDS can now be treated by V‐V ECMO support. In these cases, respiratory status should be closely monitored with evaluations including the Murray score to determine the indication for ECMO.

###### 

Review and comparison of previous cases with HIV/AIDS treated with extracorporeal membrane oxygenation (ECMO)

                                                    Age (years)   Sex   New HIV diagnosis             Diagnosis                             CD4               HIV viral load (/mL)   Timing of ART initiation (pre‐, on‐, post‐ECMO)   PaO~2~ (mmHg)/F~I~O~2~ (%)   ECMO initiation (hospital day)   ECMO duration (days)    Outcome
  ------------------------------------------------- ------------- ----- ----------------------------- ------------------------------------- ----------------- ---------------------- ------------------------------------------------- ---------------------------- -------------------------------- ----------------------- -------------------------------------
  Present case                                      47            M     Yes                           HIV/AIDS                              6 cells/μL        140,000                Post                                              54.9/50                      5                                19                      Survived to discharge
  Goodman[4](#ams2364-bib-0004){ref-type="ref"}     30            F     Yes                           HIV/AIDS, PCP                         13 cells/mL       976,631                Post                                              50.1/100                     3                                7                       Survived to discharge
  Simpson[8](#ams2364-bib-0008){ref-type="ref"}     35            M     Yes                           HIV/AIDS, PCP                         NA                1,269,866              NA                                                NA/NA                        NA (7 days on MV)                27                      Survived for 6 months
  Ali[10](#ams2364-bib-0010){ref-type="ref"}        26            M     Yes                           HIV/AIDS, PCP                         84                907,302                Post                                              200 (P/F ratio)              NA                               6                       Survived to discharge
  Horikita[9](#ams2364-bib-0009){ref-type="ref"}    23            M     Yes                           HIV/AIDS, PCP                         8.5 cells/μL      550,000                On                                                48/100                       NA (ICU day 3)                   12, 14 (2nd course)     Survived to discharge
  De Rosa[6](#ams2364-bib-0006){ref-type="ref"}     24            M     Yes                           HIV/AIDS, PCP                         3 cells/mm^3^     50,728                 On                                                100 (P/F ratio)              12 (6 days on MV)                24                      Died in hospital, s/p decannulation
  Cawcutt[7](#ams2364-bib-0007){ref-type="ref"}     45            M     Yes                           HIV/AIDS, PCP                         33 cells/mL       113,000                Pre                                               59/60                        5                                57                      Died in hospital, s/p decannulation
  Gutermann[2](#ams2364-bib-0002){ref-type="ref"}   55            M     Yes                           HIV/AIDS, PCP                         9 cells/mL        80,235                 Post                                              NA/NA                        4                                4                       Survived to discharge
  Goodman[4](#ams2364-bib-0004){ref-type="ref"}     25            M     Yes                           HIV/AIDS, PCP                         36 cells/mL       622,234                Pre                                               63.6/100                     18                               69                      Died on ECMO
  Steppan[3](#ams2364-bib-0003){ref-type="ref"}     39            M     NA                            HIV/AIDS, PCP                         69 cells/mL       6,297                  Pre                                               NA/100                       12                               14                      Died on ECMO
  De Rosa[6](#ams2364-bib-0006){ref-type="ref"}     21            F     No                            HIV/AIDS, PCP                         2 cells/mm^3^     118,330                Non‐compliant, restarted                          120 (P/F ratio)              10                               20                      Survived to discharge
  Simpson[8](#ams2364-bib-0008){ref-type="ref"}     40            M     No                            HIV, disseminated Kaposi\'s sarcoma   NA                126,947                NA                                                NA                           NA (1 day on MV)                 28                      Died in ICU
  Simpson[8](#ams2364-bib-0008){ref-type="ref"}     20            F     No                            HIV, adenovirus                       NA                Undetectable           NA                                                NA                           NA (1 day on MV)                 5                       Survived for 6 months
  25                                                M             Yes   HIV/AIDS, MDR bacterial PNA   134 cells/μL                          2,220,000         Pre                    80/90                                             27 (11 days on MV)           56                               Survived to discharge   
  De Rosa[6](#ams2364-bib-0006){ref-type="ref"}     38            F     No                            HIV, HCV, *Legionella pneumophila*    170 cells/mm^3^   500                    Compliant and continued                           90 (P/F ratio)               2                                13                      Survived to discharge

ART, antiretroviral therapy; F, female; HCV, hepatitis C virus; ICU, intensive care unit; M, male; MDR, multidrug resistant; MV, mechanical ventilation; NA, not applicable; PCP, pneumocystis pneumonia; P/F, PaO~2~/FiO~2~; s/p, status post.
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To our knowledge, there have been 14 reported cases of HIV/AIDS patients with progressive respiratory failure treated with ECMO. Eleven of these 14 cases had *P. jirovecii* pneumonia. As *P. jirovecii* pneumonia was highly suspected in the present case, we managed our patient with novel HIV/AIDS for *P. jirovecii* pneumonia. The focus in the present case was on early achievement of lung rest management by the early introduction of ECMO, which is a novel approach in these types of cases. Boonsarngsuk *et al*. concluded that PEEP on the 3rd day of ventilation management was related to higher mortality in *P. jirovecii* pneumonia,[13](#ams2364-bib-0013){ref-type="ref"} so we hypothesize that lung rest settings achieved by ECMO do have benefits. In the present case, the patient needed higher PEEP settings due to worsening oxygenation before ECMO introduction. In terms of timing of ECMO initiation, it seems ideal to start ECMO within 7 days from ventilator introduction based on the ELSO guideline[12](#ams2364-bib-0012){ref-type="ref"} and Respiratory ECMO Survival Prediction (RESP) score.[14](#ams2364-bib-0014){ref-type="ref"} In addition, as Goodman *et al*.[4](#ams2364-bib-0004){ref-type="ref"} reported, patients given ECMO early during their ventilator management course showed higher survival rates (Table [3](#ams2364-tbl-0003){ref-type="table"}).

In addition, post‐ECMO ART should be considered in HIV/AIDS patients with acute respiratory distress syndrome. All cases listed in Table [3](#ams2364-tbl-0003){ref-type="table"} that received post‐ECMO ART survived. It was difficult to extract all the conditions related to the RESP score, but when age and time to starting ECMO are based on the RESP score, post‐ECMO ART achieved survival in all cases. In general, ART is not started in *P. jirovecii* pneumonia cases presenting with high *P. jirovecii* activity, because immune reconstitution induced by ART can worsen *P. jirovecii* pneumonia. Especially in severe *P. jirovecii* pneumonia requiring ECMO support, *P. jirovecii* activity is considered to be very high. Furthermore, as IRIS has been thought to cause deterioration in some cases, we believe it is more effective and safer not to start ART until patients recover to the point where they have sufficient spontaneous oxygenation and ventilation.

Conclusion {#ams2364-sec-0007}
==========

Veno‐venous ECMO achieved a favorable outcome in an HIV/AIDS patient with severe acute respiratory distress syndrome. Post‐ECMO ART is likely a key factor for success when treating severe respiratory infection in HIV/AIDS patients requiring ECMO support.
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